Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
Alaunos Therapeutics, Inc. (TCRT)
Price$1.66Cached quote
Net income
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5,000 | $10,000 | $5,000 | $2.9M | $398,000 | $0 | — | $146,000 | $6.4M | $6.9M | $4.3M | $1.4M | $800,000 | $800,000 | $667,000 | — | — | — | — | — | — | — |
| Research & development | $1.4M | $362,000 | $16.3M | $25.0M | $49.6M | $52.7M | $38.3M | $34.1M | $45.1M | $157.8M | $106.8M | $32.7M | $42.9M | $83.4M | $57.1M | $12.9M | $4.6M | — | — | — | — | — |
| Operating expenses | $4.2M | $4.8M | $34.3M | $38.0M | $77.9M | $80.4M | $57.9M | $54.1M | $59.9M | $172.2M | $124.4M | $44.9M | $58.5M | $103.0M | $72.1M | $24.5M | $12.1M | — | — | — | — | — |
| Operating income | −$4.2M | −$4.8M | −$34.3M | −$35.1M | −$77.5M | −$80.4M | −$57.9M | −$53.9M | −$53.5M | −$165.3M | −$120.1M | −$43.5M | −$57.7M | −$102.2M | −$71.4M | −$24.5M | −$12.1M | — | — | — | — | — |
| Operating margin | −84,500.00% | −48,120.00% | −685,340.00% | −1,201.40% | −19,484.67% | — | — | −36,921.92% | −837.27% | −2,409.37% | −2,772.39% | −3,168.17% | −7,214.13% | −12,771.13% | −10,704.65% | — | — | — | — | — | — | — |
| EBITDA | −$4.2M | −$4.8M | −$32.0M | −$32.3M | −$75.0M | −$79.2M | −$57.2M | −$53.3M | −$53.1M | −$165.0M | −$119.7M | −$43.0M | −$57.0M | −$101.5M | −$71.1M | −$24.4M | −$11.8M | — | — | — | — | — |
| EBITDA margin | −84,360.00% | −48,100.00% | −639,040.00% | −1,106.98% | −18,832.16% | — | — | −36,528.08% | −831.49% | −2,405.15% | −2,764.15% | −3,134.52% | −7,121.88% | −12,688.88% | −10,664.47% | — | — | — | — | — | — | — |
| Net income | −$4.2M | −$4.7M | −$4.7M | −$37.7M | −$78.8M | −$80.0M | −$117.8M | −$53.1M | −$54.3M | −$165.3M | −$120.1M | −$31.8M | −$57.1M | −$96.1M | −$63.8M | −$32.7M | −$7.6M | −$25.2M | −$26.6M | −$17.9M | −$9.5M | −$5.7M |
| Net profit margin | −83,520.00% | −46,790.00% | −93,580.00% | −1,291.24% | −19,786.68% | — | — | −36,381.51% | −850.26% | −2,409.23% | −2,772.11% | −2,314.71% | −7,138.38% | −12,016.50% | −9,561.92% | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$2.20 | -$2.92 | -$21.97 | -$26.10 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 | -$144.00 | -$46.50 | -$99.00 | -$183.00 | -$145.50 | -$106.50 | -$49.50 | — | — | — | — | — |
| Diluted EPSper diluted share | -$2.20 | -$2.92 | -$21.97 | -$26.10 | -$55.50 | -$57.00 | -$105.00 | $144.00 | -$79.50 | -$198.00 | -$144.00 | -$46.50 | -$99.00 | -$183.00 | -$145.50 | -$106.50 | -$49.50 | — | — | — | — | — |
Owners
Reported shareholders
≈4.53%of listed shares
Postma Robert W112.59K shares · Apr 29, 2026
View holders
| Holder | % owned |
|---|---|
Postma Robert W | ≈4.53%112.59K shares |
Vieser Jaime | ≈2.19%54.46K shares |
BlackRock, Inc. | 0.86%21.35K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.78%19.36K shares |
Jerman Michael Allen | ≈0.63%15.62K shares |
VANGUARD FIDUCIARY TRUST CO | 0.62%15.5K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.57%14.06K shares |
Weis Holger | ≈0.51%12.67K shares |
CITADEL ADVISORS LLC | 0.48%11.87K shares |
Groenewald Ferdinand | ≈0.43%10.78K shares |
OSAIC HOLDINGS, INC. | 0.07%1.73K shares |
Tower Research Capital LLC (TRC) | 0.07%1.62K shares |
Arax Advisory Partners | 0.05%1.22K shares |
UBS Group AG | 0.04%992 shares |
MORGAN STANLEY | 0.03%836 shares |
Vanguard Global Advisers, LLC | 0.02%501 shares |
WELLS FARGO & COMPANY/MN | 0.02%388 shares |
ROYAL BANK OF CANADA | 0.02%375 shares |
Blue Trust, Inc. | <0.01%135 shares |
Steward Partners Investment Advisory, LLC | <0.01%112 shares |
Percentages use 2.49M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2025Form 4 | Vieser JaimeDirector | BuySeries A-2 Convertible Preferred Stock · derivative | 250 | $4.49 | $1.1K | 250 |
| Jun 24, 2025Form 4 | Postma Robert WDirector | BuySeries A-2 Convertible Preferred Stock · derivative · indirect | 600 | $4.49 | $2.7K | 600 |
| Apr 11, 2025Form 4 | Postma Robert WDirector | BuySeries A-1 Convertible Preferred Stock · derivative · indirect | 500 | $2.76 | $1.4K | 500 |
| Apr 11, 2025Form 4 | Postma Robert WDirector | BuySeries A-1 Convertible Preferred Stock · derivative · indirect | 500 | $2.76 | $1.4K | 500 |
| Dec 31, 2024Form 4 | Vieser JaimeDirector | SellCommon Stock | 818 | $2.00 | $1.6K | 25.9K |